Attenuation of cytomegalovirus virulence

Details Attenuation of cytomegalovirus virulence Attenuation of cytomegalovirus virulence

2006-12-20

2009-11-03

Chen, Stacy B (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S205100, C424S230100, C435S005000

Reexamination Certificate

active

07611718

ABSTRACT:
A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.

REFERENCES:
patent: 5721354 (1998-02-01), Spaete
patent: 2007/0292455 (2007-12-01), Kemble
patent: 2008/0019945 (2008-01-01), Kemble
Beisel, 2000, “Cytomegalovirus Vaccine Development,” Jordan Reprt, 105-110.
Cha et al., Human Cytomegalovirus Clinical Isolates Carry at Least 19 Genes Not Found in Laboratory Strains, 1996, J Virol 70:78-83.
Chee et al., Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169, 1990, Curr Top Microbiol Immunol. 154, 125-169.
Cihlar et al., Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant . . . 1998, J Virol 72:5927-36.
Haberland et al.,Variation Within the Glycoprotein B Gene of Human Cytomegalovirus is Due to Homologous Recombination, 1999, J Gen Virol 80:1495-1500.
Kemble et al., 1996, “A New Generation of Live, Attenuated Cytomegalovirus (CMV) Vaccine Strains,” Interscience Conf. Antimicrob. Agents and Chem, H88.
Kemble et al., 1996, “Genetic Determinanats of CMV Virulence,” 21st Herpesvirus Workshop; 315.
Kemble et al., 1997, “Derivation of Novel, Recombinant, Live, Attenuated CMV Vaccine Strains,” 6th Int. Cytomegalovirus Workshop, A-25(49).
Kemble et al., Jul. 1999, “Development of Live, Attenuated Human Cytomegalovirus Vaccine Candidates,” 24th Inter. Herpesvirus Workshop; 13.007.
Kemble et al., Apr. 1999, “Towne/Toledo Vaccine Development,” 7th Intl. Cytomegalovirus Workshop, Brighton, U.K.
Mocarski et al., a Deletion Mutant in the Human Cytomegalovirus Gene Encoding IE1-491aa is Replication Defective Due to a Failure in Autoregulation, 1996, PNAS 93:11321-11326.
Pande et al., Cloning and Physical Mapping of a Gene Fragment Coding for a 64-kilodalton Major Late Antigen of Human Cytomegalovirus, 1984, PNAS 54:817-24.
Plotkin, Apr. 1999, “Vaccination Against Cytomegalovirus, The Changeling Demon,” Pediatr Infect Dis J., 18:313-326.
Spaete et al.,1997, Progress in Developing a CMV Vaccine, Virology Seminar; Max-von-Pettenkofer Institute und Genz, Munchen,Germany;1-13.
Spaete et al., “Controling CMV through Vaccination,” Mar. 20-22, 1998, Science Symposium; Tucson AZ.
Spaete et al., 1998, “Progress in Developing a CMV Vaccine,” Virology Seminar; University of California —Irvine.
Spector et al., Cleavage Maps for Human Cytomegalovirus DNA Strain AD169 for Restriction Endonucleases EcoRI, BgIII, and HindIII, 1982, J Virol 42:558-82.

Affiliated with

Also associated with

Rating

Attenuation of cytomegalovirus virulence does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Attenuation of cytomegalovirus virulence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuation of cytomegalovirus virulence will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4089802